Device Medical Device

(9281) Turbo Elite

Payments companies reported to CMS as associated with (9281) Turbo Elite. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$32Kassociated payments (2023-2025)

332clinicians with associated payments

2companies reporting

By year

2023 $28K

2024 $4,396

Payments reported as associated with (9281) Turbo Elite, per program year, as reported to CMS.

Who makes it

Philips Electronics North America Corporation $28K associated with (9281) Turbo Elite (2023-2025)
Philips North America LLC $4,785 associated with (9281) Turbo Elite (2023-2025)

Specialties most often involved

Vascular Surgery $12K

Interventional Cardiology $5,227

Vascular & Interventional Radiology $4,265

Cardiovascular Disease $3,920

Surgery $1,351

Physician Assistant $794

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with (9281) Turbo Elite

These are the largest totals companies reported as associated with (9281) Turbo Elite. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Roberto Corpus	Traverse City, MI	Cardiovascular Disease	$1,014.09
Jorge Salazar	Memphis, TN	Vascular & Interventional Radiology	$734.37
Salil Joshi	Memphis, TN	Vascular & Interventional Radiology	$724.13
Prateek Gupta	Germantown, TN	Vascular Surgery	$693.24
Jennifer Odell	Memphis, TN	Acute Care (Nurse Practitioner)	$640.23
Foluso Fakorede	Cleveland, MS	Interventional Cardiology	$616.23
Anton Dias Perera	Germantown, TN	Vascular Surgery	$608.01
Robert Beasley	Miami, FL	Vascular & Interventional Radiology	$497.30
Dwight Dishmon	Memphis, TN	Interventional Cardiology	$449.26
Jeff Brown	Mechanicsville, VA	Vascular Surgery	$382.31

Prescribed (9281) Turbo Elite?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.